[PDF][PDF] Challenges and opportunities for pancreatic cancer immunotherapy
AS Bear, RH Vonderheide, MH O'Hara - Cancer cell, 2020 - cell.com
Pancreatic ductal adenocarcinoma (PDA) is among the most immune-resistant tumor types.
Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression …
Its unique genomic landscape shaped by oncogenic drivers promotes immune suppression …
Palbociclib (PD0332991)—a selective and potent cyclin-dependent kinase inhibitor: a review of pharmacodynamics and clinical development
AS Clark, TB Karasic, A DeMichele, DJ Vaughn… - JAMA …, 2016 - jamanetwork.com
Importance Palbociclib (PD0332991) is a newly developed drug that received breakthrough
designation and recent US Food and Drug Administration approval in combination with …
designation and recent US Food and Drug Administration approval in combination with …
Chimeric antigen receptor-modified T cells for the treatment of solid tumors: defining the challenges and next steps
GL Beatty, M O'Hara - Pharmacology & therapeutics, 2016 - Elsevier
Chimeric antigen receptor (CAR) T cell therapy has shown promise in CD19 expressing
hematologic malignancies, but how to translate this success to solid malignancies remains …
hematologic malignancies, but how to translate this success to solid malignancies remains …
[HTML][HTML] Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 …
LJ Padrón, DM Maurer, MH O'Hara, EM O'Reilly… - Nature medicine, 2022 - nature.com
Chemotherapy combined with immunotherapy has improved the treatment of certain solid
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma …
tumors, but effective regimens remain elusive for pancreatic ductal adenocarcinoma …
[PDF][PDF] An NK-like CAR T cell transition in CAR T cell dysfunction
Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
hematological malignancies but remains ineffective in solid tumors, due in part to CAR T cell …
Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in a phase 1 trial
GL Beatty, MH O'Hara, SF Lacey, DA Torigian… - Gastroenterology, 2018 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is resistant to T-cell–mediated immunotherapy.
We engineered T cells to transiently express a messenger RNA encoding a chimeric antigen …
We engineered T cells to transiently express a messenger RNA encoding a chimeric antigen …
Hepatocytes direct the formation of a pro-metastatic niche in the liver
The liver is the most common site of metastatic disease. Although this metastatic tropism
may reflect the mechanical trapping of circulating tumour cells, liver metastasis is also …
may reflect the mechanical trapping of circulating tumour cells, liver metastasis is also …
[HTML][HTML] Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers
AR Haas, JL Tanyi, MH O'Hara, WL Gladney… - Molecular Therapy, 2019 - cell.com
This phase I study investigated the safety and activity of lentiviral-transduced chimeric
antigen receptor (CAR)-modified autologous T cells redirected against mesothelin (CART …
antigen receptor (CAR)-modified autologous T cells redirected against mesothelin (CART …
Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1 …
KA Reiss, R Mick, MH O'Hara… - Journal of Clinical …, 2021 - ingentaconnect.com
PURPOSE Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved
as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germline …
as maintenance therapy for patients with advanced pancreatic cancer (PC) and a germline …
Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: a phase 2 randomized clinical trial
TB Karasic, MH O'Hara, A Loaiza-Bonilla… - JAMA …, 2019 - jamanetwork.com
Importance Autophagy is a mechanism of treatment resistance to chemotherapy that has a
role in the maintenance of pancreatic cancer. Hydroxychloroquine sulfate (HCQ) is an …
role in the maintenance of pancreatic cancer. Hydroxychloroquine sulfate (HCQ) is an …